A recent paper in this journal described the effect of intramuscular gold treatment on cytokine expression in synovial membranes from patients with rheumatoid arthritis.1 In that paper, the authors described changes in synovial membrane expression of interleukins (IL) IL-1a, IL-1,, IL-6, and tumour necrosis factor a in patients who had received intramuscular gold treatment. However, the authors failed to mention that some of the results had been published in another journal by a similar group of authors.2 Neither paper is cross referenced in the other, and it is not clear from these two papers whether the authors are reporting the same set of results in two different papers.
In one paper,2 the authors described a significant failure rate with blind needle biopsy of the synovial membrane, which is particularly a problem with studies involving sequential biopsying as was performed in these two studies. Our experience is similar with this technique and we have now changed to performing all synovial biopsying under direct vision through a needle arthroscope under local anaesthesia. However, despite the fact that the two patient groups appear to be similar, if not identical, in these two papers, one paper states that only seven of 18 patients recruited in the study gave We wish to question whether this conclusion is strong enough to advocate positive cytoplasmic staining as an indication for further routine testing for ENA in ANA negative patients with rheumatic diseases. In our laboratory, 5843 sera of patients with various rheumatic diseases were tested for ANA on HEp-2 cells in the past two years. Six hundred sera (10-3%) showed cytoplasmic staining, which is comparable to the 6-4% in Bath. Two hundred and ninety five of those 600 sera with cytoplasmic staining were randomly tested further for ENA by immunodiffusion: 32 (10-8%) were ENA positive (mainly SS-A and SS-B), which is similar to the 13-3% in Bath.
Of the 600 sera with cytoplasmic staining, 179 were ANA positive (2988%). This percentage is clearly less than that observed in Bath (56%). Theoretically, this discrepancy could be attributable to the study of different patient groups, but the frequency of separate diagnoses did not differ much: systemic lupus erythematosus 12% in Bath v 10% in Amsterdam; Sjogren's syndrome 4% v 3%; scleroderma 4% v 1%; rheumatoid arthritis 12% v 17%. These data indicate that the Bath and Amsterdam patient groups are quite similar.
Although our routine cascade testing stops with a negative ANA, 171 ANA negative sera, randomly selected for quality control reasons, were tested for ENA. Of these sera, 152 (89%) did not show any cytoplasmic staining. None of the remaining 19 ANA negative sera which showed a cytoplasmic staining was ENA positive, which is in contrast to the results in Bath, where five of 33 ANA negative sera which showed cytoplasmic staining were ENA positive. Moreover, in our patient group, eight of the 152 ANA negative sera without cytoplasmic staining (5-3%) were ENA positive (eight SS-A, three SS-B, one Sm).
We conclude that it is not useful routinely to follow cytoplasmic staining in HEp-2 cells in the absence of ANA by ENA testing in daily practice for rheumatic patients, because: a) ENA positive sera also occur among ANA negative sera without cytoplasmic staining, and b) the prevalence of positive ENA in ANA negative sera with cytoplasmic staining is rather low 
